Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Kanjaksha Ghosh & Kinjalka Ghosh. (2022) Monoclonal antibodies used for the management of hemataological disorders. Expert Review of Hematology 15:5, pages 443-455.
Read now
Read now
Magdalena Witkowska, Piotr Smolewski & Tadeusz Robak. (2018) Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. Expert Opinion on Investigational Drugs 27:2, pages 171-177.
Read now
Read now
Maulik Vyas, Ann-Charlott Schneider, Olga Shatnyeva, Katrin S. Reiners, Samir Tawadros, Stephan Kloess, Ulrike Köhl, Michael Hallek, Hinrich P. Hansen & Elke Pogge von Strandmann. (2016) Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. OncoImmunology 5:9.
Read now
Read now
Michael Doubek & Michal Šmída. (2015) Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. Expert Review of Hematology 8:6, pages 743-764.
Read now
Read now
Piotr Smolewski & Tadeusz Robak. (2015) The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Drug Discovery 10:7, pages 791-808.
Read now
Read now
Karen Seiter & Aleksandra Mamorska-Dyga. (2015) Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clinical Interventions in Aging 10, pages 951-961.
Read now
Read now
Articles from other publishers (6)
Kanjaksha GhoshKinjalka Ghosh. (2021) Monoclonal antibodies used for management of hematological disorders. Journal of Hematology and Allied Sciences 1, pages 12-21.
Crossref
Crossref
Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, Tanja Gardlowski, Nadine Matthies, Maulik Vyas, Lubomir Arseniev, Michael Heuser, Elke Pogge von Strandmann & Ulrike Köhl. (2017) Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. Frontiers in Immunology 8.
Crossref
Crossref
L.A. Butler, C.S. Tam & J.F. Seymour. (2017) Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood Reviews 31:5, pages 318-327.
Crossref
Crossref
M Burgess, S Mapp, R Mazzieri, C Cheung, L Chambers, S R Mattarollo, P Mollee, D Gill & N A Saunders. (2016) Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients. Oncogene 36:17, pages 2366-2376.
Crossref
Crossref
Tadeusz Robak, Jerzy Z. Blonski & Pawel Robak. (2016) Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 280-290.
Crossref
Crossref
Michael Y. Choi, George F. WidhopfIIII, Christina C.N. Wu, Bing Cui, Fitzgerald Lao, Anil Sadarangani, Joy Cavagnaro, Charles Prussak, Dennis A. Carson, Catriona Jamieson & Thomas J. Kipps. (2015) Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clinical Lymphoma Myeloma and Leukemia 15, pages S167-S169.
Crossref
Crossref